Pegasus Pharmaceuticals Inc.: Pegasus/HeartView’s Screening Device for Heart Disease Receives Marketing Approval for European Union

30. November 2006, 18:50 UhrOnline Marketingadmin

Pegasus/HeartView’s Screening Device for Heart Disease Receives Marketing Approval for European Union PALM BEACH GARDENS, FL — (MARKET WIRE) — November 30, 2006 — Pegasus/HeartView LLC (PINKSHEETS: PGUZ) today announced that they have received a CE Mark Approval for themarketing of their 6S Screening Device in Europe. The CE Mark Approvalauthorizes

Pegasus to commence a comprehensive marketing effort throughoutEurope and many other countries, which recognize the CE Mark Approval.

Pegasus/HeartView, LLC

In November, Pegasus/HeartView LLC participated with one of its OEMEuropean manufacturers in the world’s largest medical trade fair, theMEDICA 2006 SHOW, in Dusseldorf, Germany (November 14th to 17th, 2006).Pegasus/HeartView demonstrated the 6S Heart Screening Device to hundreds ofmedical professionals and met with several potential European distributorswho will participate in the marketing launch of the device, which is anadvanced, rapid and accurate screening technology for early, non-invasivedetection of heart disease.

Original is here

Popularity: 1% [?]

Related Entries

  • Introduction to Corporate Blogging
  • Endo Pharmaceuticals: Endo Pharmaceuticals to Hold 2007 Financial Guidance Conference Call
  • Los Angeles World Airports: Nationally Acclaimed Film, Focused on Van Nuys Airport, Closes Tour With VNY Screening
  • Mazal Plant Pharmaceuticals Inc.: Mazal Plant Pharmaceuticals, Inc. Announced Today the Appointment of Mr. Stanley Fass as Interim President and Director
  • IntelGenx Technologies Corp.: IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. Announce Enrollment of Phase I Pilot Study for QuitPak(R) (INT003/05)
  • NexMed, Inc.: NexMed Partner, Novartis, Commences Patient Screening for Phase 3 Clinical Trial of NM100060
  • WARNING - Affiliate Marketers Pay Attention
  • Active Biotech: Active Biotech receives 5 MSEK from VINNOVA
  • SciClone Pharmaceuticals, Inc.: SciClone Pharmaceuticals Adopts Stockholders Rights Plan
  • BurnsAdler Pharmaceuticals, Inc.: BurnsAdler Pharmaceuticals, Inc. and Serral, S.A. de C.V. Enter Into a Promotional Agreement for Gentamicin Surgical Implant

    • No comments yet.

    Write a comment:

    You must be logged in to post a comment.

    Click Here